is palbociclib a parp inhibitor?
While it remains to be investigated if CDK4/6i may regulate MYC in a tissue-specific manner, we provide evidence that Palbociclib induces downregulation of MYC and its target genes involved in HR repair, causing synthetic lethality with PARP inhibition in ovarian cancer cells.